 CAMBRIDGE, Mass.--BUSINESS WIRE--Infinity Pharmaceuticals, Inc. NASDAQ: INFI today announced that data from the front-line triple negative breast cancer TNBC cohort from the ongoing MARIO-3 clinical trial was presented during the 2020 San Antonio Breast Cancer Symposium SABCS. MARIO-3 is the Companys ongoing Phase 2 study evaluating eganelisib in a novel triple combination in the front-line setting with atezolizumab Tecentriq and nab-paclitaxel Abraxane in patients with unresecta 